Log In
Print this Print this

fasinumab (REGN475)

Also known as: formerly SAR164877

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb against nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat chronic low back pain; Treat moderate to severe osteoarthritis (OA) pain of the hip or knee; Treat pain associated with osteoarthritis (OA) of the knee
Regulatory Designation
PartnerMitsubishi Tanabe Pharma Corp.;
Teva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone









Get a free BioCentury trial today